The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%
Go back to The Lancet publishes Libtayo® (cemiplimab) data showing extended overall survival in patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ³50%| Regeneron (NASDAQ: REGN) | Delayed: 814.79 -18.77 (2.25%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $833.56 | 52 Week High | $592.36 | |||
| Open | $827.78 | 52 Week Low | $325.35 | |||
| Day High | $831.67 | P/E | 213.86 | |||
| Day Low | $814.70 | EPS | $3.81 | |||
| Volume | 585,340 | |||||
